Search results

Order by most recent / most popular / relevance

Results: 1-10 of 67

IPAB holds Bajaj’s patent to be “distinctly ahead”

Lakshmikumaran & Sridharan
-
India
-
May 22 2013

On 2nd May 2013 in LML Ltd v Bajaj Auto Limited the Intellectual Property Appellate Board (IPAB) upheld Bajaj Auto Limited's Patent IN189097 and

Revisiting efficacy: case study I

Ranjan Narula Associates
-
India
-
May 20 2013

Section 3 (d) of the Indian Patent Act has generated quite a buzz in recent times at various Intellectual Property forums and events, where the

IPAB upholds the first compulsory license granted to generic drug company

Nishith Desai Associates
-
India
-
May 10 2013

In March last year, the Controller General of Patents ("Controller") created history with a landmark judgment granting the first ever Compulsory

EU-India free trade agreement: pharmaceutical IP protection remains an issue

King & Spalding LLP
-
European Union, India
-
May 10 2013

The Indian commerce and industry minister recently submitted a letter to the Indian Parliament to update it on the progress in negotiations with the

Supreme Court offers limited definition of 'efficacy' under Patents Act

Saikrishna & Associates
-
India
-
May 7 2013

In its recent judgment in Novartis AG v Union of India the Supreme Court finally interpreted the term 'efficacy' in the context of patentability

Patent protection in India? Interim injunction refused for MSD’s patent

Nishith Desai Associates
-
India
-
May 7 2013

Delhi High Court has refused to grant an interim injunction in favor of Merck Sharp and Dohme (MSD) against Glenmark Pharmaceuticals (Glenmark) in

Indian Supreme Court rules for cancer pills patent to be made available to generics

King & Wood Mallesons
-
India
-
April 29 2013

Earlier this month, the Supreme Court of India dismissed an appeal brought by Novartis against the Indian Intellectual Property Board's 2009 decision

Indian Supreme Court invalidates anti-cancer drug patent

Marks & Clerk LLP
-
India
-
April 23 2013

The Indian Supreme Court has ruled that Novartis is not entitled to receive patent protection for its anti-cancer drug GlivecTM. The patent

Innovation going down-turn

Singh & Associates
-
India
-
April 19 2013

Innovation has always been the main objective of Patent system. Patent system is to encourage innovation and eventually result in technological

Novartis Indian Supreme Court judgment: what is efficacy for pharmaceutical invention?

Nishith Desai Associates
-
India
-
April 19 2013

The Indian Supreme Court (SC) on April 1, 2013 delivered a landmark judgment rejecting Novartis's 1998 Indian patent application for beta-crystalline

next >

Search results

IPAB holds Bajaj’s patent to be “distinctly ahead”

Revisiting efficacy: case study I

IPAB upholds the first compulsory license granted to generic drug company

EU-India free trade agreement: pharmaceutical IP protection remains an issue

Supreme Court offers limited definition of 'efficacy' under Patents Act

Patent protection in India? Interim injunction refused for MSD’s patent

Indian Supreme Court rules for cancer pills patent to be made available to generics

Indian Supreme Court invalidates anti-cancer drug patent

Innovation going down-turn

Novartis Indian Supreme Court judgment: what is efficacy for pharmaceutical invention?

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea